EMA Issues Second Negative Opinion on Omeros’ Narsoplimab Application
The European Medicines Agency issued a negative opinion on Omeros’ marketing application for narsoplimab, its treatment for stem cell transplant-associated complications. The decision marks the second negative opinion in four months.